Moreover, ESR and CRP concentrations at pre-ATT were independently associated with increased odds for occurrence of anemia at day 60 of therapy, despite an overall improvement of Hb values detected upon anti-TB treatment initiation. This evidence concerns the gene GSTM1 and anemia (phenotype).